Skip to main content
TipRanks
Go Ultimate75% OFF

Arch Biopartners (ARCH) AI Stock Analysis

51 Followers
TSE:ARCH

Arch Biopartners

(TSXV:ARCH)

Select Model
Rating:48Neutral
Price Target:CAD 0.87â–¼(-7.34% Downside)
Action:upgraded
Date:11/04/26

Arch Biopartners yields a severely depressed overall score, driven primarily by its critical financial vulnerability. The company's complete lack of revenue, significant capital deficit, and ongoing cash burn pose substantial solvency risks. While technical indicators suggest neutral momentum and some stabilization above the 200-day moving average, the speculative valuation and deep unprofitability heavily outweigh any technical support, making this a highly distressed profile.

Positive Factors
Focused clinical pipelineA clearly defined therapeutic focus can help a small biotechnology company concentrate capital and research resources on a specific unmet medical need. LSALT peptide provides a central development program and a potential path toward clinical differentiation if its intended protective effects are validated.
Negative Factors
No current revenueThe absence of current revenue means the company has not yet established a commercialized source of operating income. This leaves financial performance dependent on development progress and future financing rather than customer demand, increasing the time and execution required to reach self-sustaining operations.

Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)

-80%-60%-40%-20%0%20%40%TSE:ARCH-10.48%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 63.86M
Dividend Yield
―
Average Volume (3M)
43.19K
Price to Earnings (P/E)
-22.1
Beta (1Y)
1.19
Revenue Growth
―
EPS Growth
-15.53%
Country
Canada
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address...

Arch Biopartners Financial Statement Overview

Summary

Arch Biopartners faces extreme financial distress. The company generated zero revenue in the trailing twelve months, leading to widening net losses and continuous cash burn. Combined with a severe capital deficit, negative equity, and debt that substantially outweighs its minimal asset base, solvency and dilution risks are critical.

Income Statement

12Very Negative

Balance Sheet

8Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue002.12M1.98M964.68K3.89M
Gross Profit00-1.66M-129.00K-503.00K-150.00K
EBITDA-2.58M-1.29M-75.40K-335.99K-101.90K-76.62K
Net Income-2.83M-1.55M-3.92M-3.33M-1.41M-1.17M
Balance Sheet
Total Assets57.22K104.53K935.62K1.17M621.64K2.67M
Cash, Cash Equivalents and Short-Term Investments2,9142,1022,970831.27K506.35K448.24K
Total Debt2.73M2.84M2.77M5.02M4.41M5.16M
Total Liabilities4.04M3.99M5.28M6.68M5.09M6.55M
Stockholders Equity-3.99M-3.88M-4.35M-5.51M-4.47M-3.88M
Cash Flow
Free Cash Flow-1.72M-1.58M-2.33M-234.08K-1.08M-2.98M
Operating Cash Flow-1.72M-1.58M-2.33M-234.07K-1.08M-2.98M
Investing Cash Flow000000
Financing Cash Flow1.55M1.58M1.50M559.00K-421.37K2.78M

Arch Biopartners Technical Analysis

Technical Analysis SentimentPositive
Last Price0.94

Price Trends

50DMA0.87Positive
100DMA0.91Positive
200DMA0.76Positive

Market Momentum

MACD0.02Negative
RSI52.83Neutral
STOCH59.18Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Positive. The current price of 0.94 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.87, and above the 200-day MA of 0.76, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 59.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:ARCH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:ARCHTSE:ARCH48NeutralCAD 63.86M-22.1274.79%――-15.53%
TSE:BCTTSE:BCT45NeutralCAD 40.65M-0.35-170.70%――87.90%
TSE:MSCLTSE:MSCL44NeutralCAD 188.83M-2.86-77.81%――-32.01%
TSE:MDNATSE:MDNA39UnderperformCAD 13.97M-0.88-861.02%――-21.17%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%TSE:ARCHTSE:MSCLTSE:MDNATSE:BCTTSE:METXTSE:ONCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:ARCH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:ARCHArch Biopartners0.94-0.10-9.62%
TSE:MSCLSatellos Bioscience Inc.8.62-0.02-0.23%
TSE:MDNAMedicenna Therapeutics0.18-1.19-86.86%
TSE:BCTBriaCell Therapeutics4.66-5.58-54.50%
TSE:METXME Therapeutics Holdings, Inc.1.05-1.98-65.35%
TSE:ONCOOnco-Innovations Ltd.1.470.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026